Although this vaccine’s effectiveness has been shown only on a limited number of animals, it is a further step towards protection of dogs against this disease. These results, confirmed indeed by the first, highly encouraging, data from a large-scale clinical trial currently under way (phase III), are promising for efforts to reduce transmission of leishmaniasis to humans. They also point to new lines of investigation for elaborating a possible human vaccine. An integrated research project, involving several IRD groups (2), has just been set up in India, to work on this. It should lead to an assessment of the effectiveness of such a vaccine in humans.
(1) The finding of these proteins furthermore necessitated the development, achieved in 1992, of suitable culture media (patented), with the attached proteins removed. The media normally used ijn fact contain many protein-containing compounds (serumalbumins, albumins etc.) which prevent specific isolation of the proteins excreted by the parasite. References : Lemesre J.L., Blanc M.P., Grébaut P., Zilberfard V. et Carrière V. (1994). Culture continue de formes amastigotes de Leishmanies en condition axénique. Réalisation du cycle évolutif in vitro. Médecine et Armées, 22 (1), 99 and Merlen T, Sereno D, Brajon N. and Lemesre J.L. (1999). Leishmania Spp: completely defined medium without serum and macromolecules (CDM/LP) for the continuous in vitro cultivation of infective promastigote forms. Am. J. Trop. Med. Hyg., 60 (1), 41-50. Brevets : Lemesre J.L. (1993). "Procédé de culture in vitro de différents stades parasitaires obtenus et applications biologiques". Brevet français, FR n° 93 05779 ; Lemesre J.L. (1994)."Method for the culture in vitro of different stages of tissue parasites".Brevet international, PCT/FR N° 94/00577.
(2) The project, entitled « Study of the host and parasite factors determining the outcome of visceral leishmaniasis: applica
Source:Institut de Recherche Pour le D茅veloppement